Cary, NC – November 17, 2013. BMG LABTECH, Inc. – the Microplate Reader Company – and InvivoSciences, Inc. – a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery – announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies. Employing an automated system, 3D heart tissues are fabricated with cardiomyocytes derived from human induced pluripotent stem cells. The ultra- sensitive plate reader, CLARIOstar®, will analyze rapid beat-to-beat changes (up to 50 Hz) in the fluorescence intensities of dyes that indicate physiological states in engineered 3D heart tissue after drug/compound application.
In addition, InvivoSciences, Inc. is sponsoring a workshop during Cell Based Assays Summit in Munich Germany, December 02-04, 2013. BMG LABTECH will have a short presentation at the workshop to discuss applications of microplate readers in cell and tissue based assays.
While on January 20th workshop tutorial at Society for Laboratory Automation and Screening (SLAS) in San Diego, CA.
These Workshops will highlight applications of pluripotent cells and engineered tissues in drug discovery, including disease model generation as well as personalized and regenerative medicine. Cost-effective and flexible approaches of pluripotent cell culture and its scale up procedures will be presented.
“InvivoSciences has established themselves as a leader in engineered 3D tissues using pluripotent stem cells,” said E.J. Dell, Ph.D., International Marketing Director of BMG LABTECH. “We are pleased to partner with them to create a drug discovery platform that is biologically more relevant to researchers.” Ayla Annac, Co-founder and CEO of InvivoSciences comments, “We are especially proud and pleased to establish a long-term relationship with the leading developer and internationally-recognized manufacture of microplate readers, BMG LABTECH.”